TTI-621 is an investigational agent being developed by Trillium Therapeutics Inc. for the treatment of cutaneous T-cell lymphoma and other cancer types. TTI-621 is designed to target and block a protein called CD47. CD47 is present on cancer cells and is used by cancer cells to hide from the body’s immune system. Blocking CD47 with TTI-621 may help the body’s immune system find and destroy the cancer cells.
Study TTI-621-02 (NCT02890368) is a multicenter, open-label, phase 1 clinical trial testing TTI-621 in patients with relapsed or refractory percutaneously accessible solid tumors or mycosis fungoides (a form of cutaneous T-cell lymphoma). In this study, TTI-621 is injected directly into the tumor or skin lesions (intralesional injection). Most patients enrolled into this study received TTI-621 as a single therapy; for some tumor types, TTI-621 may be administered with either pegylated interferon-alpha, a PD-1/PD-L1 inhibitor, an oncolytic virus or radiation.
Based on data from 27 patients with relapsed/refractory mycosis fungoides/Sézary syndrome who have been treated with TTI-621 in this study, administration of TTI-621 by intralesional injection was well tolerated, with no serious treatment-related adverse events. Reductions in treated lesions were observed in 91% of patients, with 41% observing significant lesion improvement. The onset of these responses occurred rapidly within the first 2 weeks of treatment. Initial evidences suggest that TTI-621 may also have effects in non-treated areas distal to the site of injection.
This study is currently recruiting patients. For more information, including a list of trial locations, please refer to ClinicalTrials.gov web.